To the Editor: Dr De Roock and colleagues1 studied the effect of KRAS p.G13D mutation on cetuximab efficacy in chemotherapy-refractory metastatic colorectal cancer. The authors concluded that patients with KRAS p.G13D-mutated tumors have longer overall survival and progression-free survival than patients with other KRAS -mutated tumors.
Mao C, Tang J. KRAS Genotypes and Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab. JAMA. 2011;305(6):564-566. doi:10.1001/jama.2011.86